Overview
Ultima is the venture arm of BCS Capital DIFC. It invests capital and provides strategic support to startups and growth-stage companies across Europe and the Middle East. Backed by BCS’s $5 billion assets under management and with offices in New York, London, Dubai, and Limassol, Ultima helps portfolio companies scale by connecting them to BCS’s networks, clients, and resources. Its investment history includes Alto Pharmacy, Rapyd, Byju’s, Acronis, Trax Retail, showing activity across fintech, software, and retail tech. Unlike many investors, Ultima leverages BCS’s multi-asset platform and regional reach to bridge markets between Europe and the MENA region. The goal is to back ambitious companies with growth potential and help them grow through capital, guidance, and access to a global network.
Work here?Claim your company
Simplify's take
What believers are saying
- Singapore’s NPM Phase III selected Ultima on November 2, 2026 for population genomics.
- October 2026 launches doubled output and expanded Ultima’s addressable installed-base economics.
- Precure, IMU Biosciences, and BaseClear signal multiple 2026 commercial validation points.
What critics are saying
- Illumina still owns clinical sequencing standards, squeezing Ultima’s adoption and pricing power.
- If UG200 reliability slips, Singapore’s NPM and UK Biobank programs become brutal reference failures.
- Capital intensity stays existential; one failed commercialization cycle can starve Ultima before scale.
What makes The Ultima unique
- Ultima Genomics sells wafer-scale sequencing, not incremental instrument upgrades.
- Its UG200 and Solaris 2.0 Max target a stated $60 human genome.
- October 2026 paired-end sequencing and NVIDIA-DeepVariant workflows deepen its platform moat.
Help us improve and share your feedback! Did you find this helpful?